5 november 2023: Zie ook deze search op microbioom - darmflora voor artikelen op onze website over de darmflora - microbioom.

5 november 2023: zie ook dit artikel: https://kanker-actueel.nl/darmbacterien-beinvloeden-werking-van-veel-medicijnen-waaronder-cholesterolverlagers-antidepressiva-en-de-anticonceptiepil-het-microbioom-darmflora-blijkt-grote-rol-te-spelen-in-onze-gezondheid-en-immuunsysteem.html

Wie advies wilt over hoe het microbioom te verbeteren zou contact op kunnen nemen met deze website: Www.microbiome-Center.nl Voor zowel artsen als individuele burgers staat een groep van artsen en wetenschappers klaar om u een persoonlijk advies te geven.

5 november 2023: bronnen, Nature, website UMCG,

Mensen met verdachte darmpoliepen vertonen significante verschillen in hun darmmicrobioom (darmflora) vergeleken met de algemene bevolking al 5 jaar voordat de darmpoliepen zich ontwikkelen. Dat blijkt uit de resultaten van het Dutch Microbiome Project uitgevoerd door onderzoekers van het UMCG onder leiding van onderzoeksleider Ranko Gacesa, PhD, van de afdeling Gastro-enterologie, Universiteit van Groningen, Nederland.

Ook blijkt uit hun onderzoek dat bepaalde bacteriën een rol spelen bij ontwikkelen van ziektes en andere bacteriën juist de gezondheid kunnen bevorderen, waardoor de samenstelling van het microbioom - darmflora aan te sturen is.

Uit een andere reviewstudie blijkt een gezonde darmflora - microbioom te stimuleren is met vooral plantaardige voeding en daarmee kan een gezonde microbioom - darmflora ook een stimulerende rol spelen bij patiënten die immuuntherapie krijgen voor hun vormen van kanker.

Achtereenvolgens wat extra informatie over bovenstaande en links naar abstracten en studierapporten. Te beginnen met de Groningse studie

"De bevindingen suggereren een mogelijke rol voor de darmmicrobiota bij de ontwikkeling van darmpoliepen en kanker. "Het suggereert ook dat darmbacteriën de momenteel gebruikte niet-invasieve fecale tests voor de detectie van darmpoliepen kunnen verbeteren en zelfs dat microbioom-modulerende therapieën een rol kunnen spelen bij de preventie van darmkanker", zegt dr. / prof. Ranko Gacesa, die de prijs voor beste onderzoek won en die de resultaten presenteerde op de United European Gastroenterology. UEG) Week 2023.

De onderzoekers vonden ook dat veel ziekten beïnvloed worden door de samenstelling van het microbioom. Er zijn specifieke groepen bacteriën in het microbioom die geassocieerd zijn met veel verschillende ziekten, dit ongeacht het precieze ziektebeeld. Het omgekeerde bleek ook het geval. Er zijn ook bacteriën in het microbioom die juist geassocieerd zijn met een betere gezondheid. Hierdoor waren de onderzoekers in staat om het karakter en het patroon van een gezond microbioom vast te stellen. En welke specifieke bacteriën een rol speelden bij bepaalde ziektes en welke bacteriën de gezondheid stimuleerden.

De onderzoekers gingen ook na welke factoren de samenstelling van het microbioom beïnvloeden. Naast bekende factoren als dieet, medicatiegebruik en ziekte, blijken ook andere factoren een effect te hebben. Het microbioom blijkt bijvoorbeeld gezonder als iemand in een groenere en minder vervuilde omgeving woont, en er minder fijnstof in de lucht is.
Ook hebben zij vastgesteld dat ook de leefomstandigheden van de ouders van de betreffende persoon invloed hebben. Als bijvoorbeeld iemand ouders heeft die roken of is opgegroeid in een landelijke omgeving, dan heeft dat ook invloed op zijn of haar microbioom.

Op de website van het UMCG staat een uitgebreidere uitleg van de studie zoals gepubliceerd in Nature (abstract verderop in dit artikel):

UMCG-onderzoekers identificeren samenstelling van gezonde darmflora

Inzichten in welke bacteriën in het microbioom geassocieerd zijn met ziekte en welke juist met gezondheid

14 april 2022

Er wordt vaak gesproken over gezonde darmflora, maar tot op heden is het eigenlijk niet duidelijk wat daarmee precies bedoeld wordt. Door grootschalig onderzoek hebben onderzoekers van het UMCG de samenstelling van een gezond microbioom nu goed kunnen bepalen. Zij konden dit vaststellen nadat zij van ruim 8200 Lifelines-deelnemers de samenstelling van het microbioom zeer uitvoerig hebben geanalyseerd. Zij konden hierdoor niet alleen een catalogus van het microbioom samenstellen, maar ook aangeven welke bacteriën in het microbioom betrokken zijn bij ziekte en welke juist bij gezondheid; dit heeft grote waarde voor vervolgonderzoek en medische toepassingen. Ook bleek uit hun studie dat niet alleen iemands huidige leefomstandigheden, maar ook omstandigheden uit het verleden, zoals de leefomgeving in de kindertijd, invloed hebben op de samenstelling van het microbioom. En dat samenwonen in een huishouden ervoor zorgt dat het microbioom van de betreffende personen grotendeels dezelfde samenstelling hebben. De bevindingen zijn vandaag gepubliceerd in het vooraanstaande wetenschappelijke magazine Nature.>>>>>>>lees verder

Hier het abstract van de studie:

Article
Published: 13 April 2022

Environmental factors shaping the gut microbiome in a Dutch population

Nature volume 604, pages732–739 (2022)Cite this article

35k Accesses
146 Citations
322 Altmetric
Metricsdetails

Abstract

The gut microbiome is associated with diverse diseases1,2,3, but a universal signature of a healthy or unhealthy microbiome has not been identified, and there is a need to understand how genetics, exposome, lifestyle and diet shape the microbiome in health and disease. Here we profiled bacterial composition, function, antibiotic resistance and virulence factors in the gut microbiomes of 8,208 Dutch individuals from a three-generational cohort comprising 2,756 families. We correlated these to 241 host and environmental factors, including physical and mental health, use of medication, diet, socioeconomic factors and childhood and current exposome. We identify that the microbiome is shaped primarily by the environment and cohabitation. Only around 6.6% of taxa are heritable, whereas the variance of around 48.6% of taxa is significantly explained by cohabitation. By identifying 2,856 associations between the microbiome and health, we find that seemingly unrelated diseases share a common microbiome signature that is independent of comorbidities. Furthermore, we identify 7,519 associations between microbiome features and diet, socioeconomics and early life and current exposome, with numerous early-life and current factors being significantly associated with microbiome function and composition. Overall, this study provides a comprehensive overview of gut microbiome and the underlying impact of heritability and exposures that will facilitate future development of microbiome-targeted therapies.

Een andere studie laat zien dat een gezonde microbioom - darmflora en natuurlijke voeding een stimulerende rol kan spoelen bij vormen van immuuntherapie.

Bacterial taxa in stool that are associated with specific dietary components, markers of nutrition and body composition, and response to ICI cancer treatment. Selected bacterial taxa are shown that have been reported in at least two studies. Specific taxonomic levels are denoted by prefix: c_ class; f_ family; g_ genus; s_ species.

Klik op de titel voor het volledige studierapport:

Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle

BJC Reports volume 1, Article number: 5 (2023) Cite this article

1649 Accesses
27 Altmetric
Metricsdetails

Abstract

The gut microbiome is emerging as an important predictor of response to immune checkpoint inhibitor (ICI) therapy for patients with cancer. However, several nutrition-related patient characteristics, which are themselves associated with changes in gut microbiome, are also prognostic markers for ICI treatment response and survival. Thus, increased abundance of Akkermansia muciniphila, Phascolarctobacterium, Bifidobacterium and Rothia in stool are consistently associated with better response to ICI treatment. A. muciniphila is also more abundant in stool in patients with higher muscle mass, and muscle mass is a strong positive prognostic marker in cancer, including after ICI treatment. This review explores the complex inter-relations between the gut microbiome, diet and patient nutritional status and the correlations with response to ICI treatment. Different multivariate approaches, including archetypal analysis, are discussed to help identify the combinations of features which may select patients most likely to respond to ICI treatment.

Conclusions

Despite the use of current tumour-based biomarkers it remains challenging to predict whether a given individual will have sustained response to ICI treatment. The patient’s gut microbiome profile and many nutrition-related features provide additional prognostic information, but it is not clear how best to incorporate these data to improve ICI treatment planning. A combination of statistical modelling and machine-learning techniques, such as archetypal analysis, is proposed to identify patterns or combinations of features associated with better outcomes after ICI treatment. This pattern-recognition approach may also identify mechanistically important co-dependencies between nutritional and gut microbiome data and lay the groundwork for future intervention studies to improve outcomes.

Data availability

Not applicable.

References

Wang Y, Tong Z, Zhang W, Zhang W, Buzdin A, Mu X, et al. FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients. Front Oncol. 2021;11:683419.

Article CAS PubMed PubMed Central Google Scholar
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6.

Article CAS PubMed Google Scholar
Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2005;17:133–44.

Article CAS PubMed Google Scholar
Wiest N, Majeed U, Seegobin K, Zhao Y, Lou Y, Manochakian R. Role of immune checkpoint inhibitor therapy in advanced EGFR-mutant non-small cell lung cancer. Front Oncol. 2021;11:751209.

Article CAS PubMed PubMed Central Google Scholar
Facchinetti F, Di Maio M, Perrone F, Tiseo M. First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. Transl Lung Cancer Res. 2021;10:2917–36.

Article CAS PubMed PubMed Central Google Scholar
Ekmekciu I, von Klitzing E, Fiebiger U, Escher U, Neumann C, Bacher P, et al. Immune responses to broad-spectrum antibiotic treatment and fecal microbiota transplantation in mice. Front Immunol. 2017;8:397.

Article PubMed PubMed Central Google Scholar
Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565:600–5.

Article CAS PubMed Google Scholar
Mortaz E, Tabarsi P, Mansouri D, Khosravi A, Garssen J, Velayati A, et al. Cancers related to immunodeficiencies: update and perspectives. Front Immunol. 2016;7:365.

Article PubMed PubMed Central Google Scholar
Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–6.

Article CAS PubMed PubMed Central Google Scholar
Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 2017;19:848–55.

Article CAS PubMed PubMed Central Google Scholar
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.

Article CAS PubMed Google Scholar
Routy B, Le Chatelier E, Derosa L, Duong C, Alou M, Daillère R, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359:91–7.

Article CAS PubMed Google Scholar
Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019;7:193.

Article CAS PubMed PubMed Central Google Scholar
Li L, Ye J. Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: a Chinese population-based study. Medicine. 2020;99:e21788.

Article CAS PubMed PubMed Central Google Scholar
Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, et al. The gut microbiome is associated with clinical response to anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res. 2020;8:1251–61.

Article PubMed Google Scholar
Wind TT, Gacesa R, Vich Vila A, de Haan JJ, Jalving M, Weersma RK, et al. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. Melanoma Res. 2020;30:235–46.

Article CAS PubMed Google Scholar
Mao J, Wang D, Long J, Yang X, Lin J, Song Y, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. 2021;9:e003334.

Article PubMed PubMed Central Google Scholar
Zhang F, Ferrero M, Dong N, D’Auria G, Reyes-Prieto M, Herreros-Pomares A, et al. Analysis of the gut microbiota: an emerging source of biomarkers for immune checkpoint blockade therapy in non-small cell lung cancer. Cancers. 2021;13:2514.

Article CAS PubMed PubMed Central Google Scholar
Lee KA, Thomas AM, Bolte LA, Bjork JR, de Ruijter LK, Armanini F, et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med. 2022;28:535–44.

Article CAS PubMed PubMed Central Google Scholar
Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019;14:1378–89.

Article CAS PubMed Google Scholar
Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022;28:315–24.

Article CAS PubMed PubMed Central Google Scholar
Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020;78:195–206.

Article CAS PubMed Google Scholar
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368–79.

Article CAS PubMed Google Scholar
Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8:e1568812.

Article PubMed PubMed Central Google Scholar
Lee SH, Cho SY, Yoon Y, Park C, Sohn J, Jeong JJ, et al. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat Microbiol. 2021;6:277–88.

Article CAS PubMed Google Scholar
Yang M, Wang Y, Yuan M, Tao M, Kong C, Li H, et al. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: an up-to-date systematic review and meta-analysis. Int Immunopharmacol. 2020;88:106876.

Article CAS PubMed Google Scholar
Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602–9.

Article CAS PubMed Google Scholar
Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients. Science. 2021;371:595–602.

Article CAS PubMed PubMed Central Google Scholar
Zhang WQ, Zhao SK, Luo JW, Dong XP, Hao YT, Shan HL, et al. Alterations of fecal bacterial communities in patients with lung cancer. Am J Transl Res. 2018;10:3171–85.

CAS PubMed PubMed Central Google Scholar
Kartal E, Schmidt TSB, Molina-Montes E, Rodriguez-Perales S, Wirbel J, Maistrenko OM, et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut. 2022;71:1359–72.

Article CAS PubMed Google Scholar
Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015;6:6528.

Article CAS PubMed Google Scholar
Gupta A, Dhakan DB, Maji A, Saxena R, Vishnu Prasoodanan PK, Mahajan S, et al. Association of Flavonifractor plautii, a flavonoid-degrading bacterium, with the gut microbiome of colorectal cancer patients in India. mSystems. 2019;4:e00438–19.

Article CAS PubMed PubMed Central Google Scholar
Ubachs J, Ziemons J, Soons Z, Aarnoutse R, van Dijk DPJ, Penders J, et al. Gut microbiota and short-chain fatty acid alterations in cachectic cancer patients. J Cachexia Sarcopenia Muscle. 2021;12:2007–21.

Article PubMed PubMed Central Google Scholar
Martin L, Muscaritoli M, Bourdel-Marchasson I, Kubrak C, Laird B, Gagnon B, et al. Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis. J Cachexia Sarcopenia Muscle. 2021;12:1189–202.

Article PubMed PubMed Central Google Scholar
Enaud R, Hooks KB, Barre A, Barnetche T, Hubert C, Massot M, et al. Intestinal inflammation in children with cystic fibrosis is associated with Crohn’s-like microbiota disturbances. J Clin Med. 2019;8:645.

Article CAS PubMed PubMed Central Google Scholar
Wei Y, Li Y, Yan L, Sun C, Miao Q, Wang Q, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut. 2020;69:569–77.

Article CAS PubMed Google Scholar
Bindels LB, Neyrinck AM, Claus SP, Le Roy CI, Grangette C, Pot B, et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. ISME J. 2016;10:1456–70.

Article CAS PubMed Google Scholar
Bindels LB, Beck R, Schakman O, Martin JC, De Backer F, Sohet FM, et al. Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PLoS ONE. 2012;7:e37971.

Article CAS PubMed PubMed Central Google Scholar
Ni Y, Lohinai Z, Heshiki Y, Dome B, Moldvay J, Dulka E, et al. Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients. ISME J. 2021;15:3207–20.

Article CAS PubMed PubMed Central Google Scholar
Zackular JP, Rogers MA, Ruffin MTT, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res. 2014;7:1112–21.

Article CAS Google Scholar
Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66:70–8.

Article CAS PubMed Google Scholar
Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS ONE. 2013;8:e70803.

Article CAS PubMed PubMed Central Google Scholar
Ndeh D, Gilbert HJ. Biochemistry of complex glycan depolymerisation by the human gut microbiota. FEMS Microbiol Rev. 2018;42:146–64.

Article CAS PubMed Google Scholar
Hillman ET, Kozik AJ, Hooker CA, Burnett JL, Heo Y, Kiesel VA, et al. Comparative genomics of the genus Roseburia reveals divergent biosynthetic pathways that may influence colonic competition among species. Microb Genom. 2020;6:7–24.

Google Scholar
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–63.

Article CAS PubMed Google Scholar
Dominianni C, Sinha R, Goedert JJ, Pei Z, Yang L, Hayes RB, et al. Sex, body mass index, and dietary fiber intake influence the human gut microbiome. PLoS ONE. 2015;10:e0124599.

Article PubMed PubMed Central Google Scholar
Lin D, Peters BA, Friedlander C, Freiman HJ, Goedert JJ, Sinha R, et al. Association of dietary fibre intake and gut microbiota in adults. Br J Nutr. 2018;120:1014–22.

Article CAS PubMed PubMed Central Google Scholar
Wu GD, Chen J, Hoffmann C, Bittinger K. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105–8.

Article CAS PubMed PubMed Central Google Scholar
Chen HM, Yu YN, Wang JL, Lin YW, Kong X, Yang CQ, et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr. 2013;97:1044–52.

Article CAS PubMed Google Scholar
Zhang C, Bjorkman A, Cai K, Liu G, Wang C, Li Y, et al. Impact of a 3-months vegetarian diet on the gut microbiota and immune repertoire. Front Immunol. 2018;9:908.

Article PubMed PubMed Central Google Scholar
Davis JA, Collier F, Mohebbi M, Pasco JA, Shivappa N, Hébert JR, et al. The associations of butyrate-producing bacteria of the gut microbiome with diet quality and muscle health. Gut Microbiome. 2021;2:e2.
Castro-Mejia JL, Khakimov B, Krych L, Bulow J, Bechshoft RL, Hojfeldt G, et al. Physical fitness in community-dwelling older adults is linked to dietary intake, gut microbiota, and metabolomic signatures. Aging Cell. 2020;19:e13105.

Article CAS PubMed PubMed Central Google Scholar
Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen MAY, Bolte LA, et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature. 2022;604:732–9.

Article CAS PubMed Google Scholar
Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352:565–9.

Article CAS PubMed PubMed Central Google Scholar
Marconi S, Durazzo A, Camilli E, Lisciani S, Gabrielli P, Aguzzi A, et al. Food composition databases: considerations about complex food matrices. Foods. 2018;7:2.

Article PubMed PubMed Central Google Scholar
Wang N, Hatcher DW, Tyler RT, Toews R, Gawalko EJ. Effect of cooking on the composition of beans (Phaseolus vulgaris L.) and chickpeas (Cicer arietinum L.). Food Res Int. 2010;43:589–94.

Article CAS Google Scholar
Trisat K, Wong-on M, Lapphanichayakool P, Tiyaboonchai W, Limpeanchob N. Vegetable juices and fibers reduce lipid digestion or absorption by inhibiting pancreatic lipase, cholesterol solubility and bile acid binding. Int J Vegetable Sci. 2016;23:260–9.

Article Google Scholar
Johnson AJ, Vangay P, Al-Ghalith GA, Hillmann BM, Ward TL, Shields-Cutler RR, et al. Daily sampling reveals personalized diet-microbiome associations in humans. Cell Host Microbe. 2019;25:789–802.e5.

Article CAS PubMed Google Scholar
Nasrah R, Kanbalian M, Van Der Borch C, Swinton N, Wing S, Jagoe RT. Defining the role of dietary intake in determining weight change in patients with cancer cachexia. Clin Nutr. 2018;37:235–41.

Article CAS PubMed Google Scholar
Hutton JL, Martin L, Field CJ, Wismer WV, Bruera ED, Watanabe SM, et al. Dietary patterns in patients with advanced cancer- implications for anorexia-cachexia therapy. Am J Clin Nutr. 2006;84:1163–70.

Article CAS PubMed Google Scholar
Ui Dhuibhir P, Barrett M, O’Donoghue N, Gillham C, El Beltagi N, Walsh D. Self-reported and objective taste and smell evaluation in treatment-naive solid tumour patients. Support Care Cancer. 2020;28:2389–96.

Article PubMed Google Scholar
Drareni K, Dougkas A, Giboreau A, Laville M, Souquet PJ, Bensafi M. Relationship between food behavior and taste and smell alterations in cancer patients undergoing chemotherapy: a structured review. Semin Oncol. 2019;46:160–72.

Article PubMed Google Scholar
Nolden A, Joseph PV, Kober KM, Cooper BA, Paul SM, Hammer MJ, et al. Co-occurring gastrointestinal symptoms are associated with taste changes in oncology patients receiving chemotherapy. J Pain Symptom Manage. 2019;58:756–65.

Article PubMed PubMed Central Google Scholar
Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, et al. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer. 2014;135:763–73.

Article CAS PubMed Google Scholar
Coa KI, Epstein JB, Ettinger D, Jatoi A, McManus K, Platek ME, et al. The impact of cancer treatment on the diets and food preferences of patients receiving outpatient treatment. Nutr Cancer. 2015;67:339–53.

Article PubMed PubMed Central Google Scholar
Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22:470–9.

Article CAS PubMed PubMed Central Google Scholar
Deans DA, Tan BH, Wigmore SJ, Ross JA, de Beaux AC, Paterson-Brown S, et al. The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br J Cancer. 2009;100:63–9.

Article CAS PubMed PubMed Central Google Scholar
Bressan V, Bagnasco A, Aleo G, Catania G, Zanini MP, Timmins F, et al. The life experience of nutrition impact symptoms during treatment for head and neck cancer patients: a systematic review and meta-synthesis. Support Care Cancer. 2017;25:1699–712.

Article PubMed Google Scholar
Kim DY, Moon HS, Kwon IS, Park JH, Kim JS, Kang SH, et al. Self-expandable metal stent of esophagogastric junction versus pyloric area obstruction in advanced gastric cancer patients: retrospective, comparative, single-center study. Medicine. 2020;99:e21621.

Article PubMed PubMed Central Google Scholar
Bye A, Jordhoy MS, Skjegstad G, Ledsaak O, Iversen PO, Hjermstad MJ. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013;21:219–27.

Article PubMed Google Scholar
Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15:e447–e60.

Article PubMed Google Scholar
Gee C, Fleuret C, Wilson A, Levine D, Elhusseiny R, Muls A, et al. Bile acid malabsorption as a consequence of cancer treatment: prevalence and management in the national leading centre. Cancers. 2021;13:6213.

Article CAS PubMed PubMed Central Google Scholar
McJunkin B, Fromm H, Sarva RP, Amin P. Factors in the mechanism of diarrhea in bile acid malabsorption: fecal pH—a key determinant. Gastroenterology. 1981;80:1454–64.

Article CAS PubMed Google Scholar
Ilhan ZE, Marcus AK, Kang DW, Rittmann BE, Krajmalnik-Brown R. pH-mediated microbial and metabolic interactions in fecal enrichment cultures. mSphere. 2017;2:e00047–17.

Article CAS PubMed PubMed Central Google Scholar
Morel H, Raynard B, d’Arlhac M, Hauss PA, Lecuyer E, Oliviero G, et al. Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer. Lung Cancer. 2018;126:55–63.

Article PubMed Google Scholar
Carnie L, Abraham M, McNamara MG, Hubner RA, Valle JW, Lamarca A. Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Pancreatology. 2020;20:1682–8.

Article CAS PubMed Google Scholar
Le-Rademacher J, Lopez C, Wolfe E, Foster NR, Mandrekar SJ, Wang X, et al. Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. J Cachexia Sarcopenia Muscle. 2020;11:1501–8.

Article PubMed PubMed Central Google Scholar
Mansoor W, Roeland EJ, Chaudhry A, Liepa AM, Wei R, Knoderer H, et al. Early weight loss as a prognostic factor in patients with advanced gastric cancer: analyses from REGARD, RAINBOW, and RAINFALL phase III studies. Oncologist. 2021;26:e1538–e47.

Article CAS PubMed PubMed Central Google Scholar
Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Nutritional deterioration in cancer: the role of disease and diet. Clinical Oncol. 2003;15:443–50.

Article CAS Google Scholar
Hakozaki T, Nolin-Lapalme A, Kogawa M, Okuma Y, Nakamura S, Moreau-Amaru D, et al. Cancer cachexia among patients with advanced non-small-cell lung cancer on immunotherapy: an observational study with exploratory gut microbiota analysis. Cancers. 2022;14:5405.

Article CAS PubMed PubMed Central Google Scholar
Miyawaki T, Naito T, Doshita K, Kodama H, Mori M, Nishioka N, et al. Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer. Thorac Cancer. 2022;13:2064–74.
Shijubou N, Sumi T, Yamada Y, Nakata H, Mori Y, Chiba H. Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer. J Cancer Res Clin Oncol. 2022;148:1893–901.

Article CAS PubMed Google Scholar
Lee CS, Devoe CE, Zhu X, Stein Fishbein J, Seetharam N. Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer. Lung Cancer Manag. 2020;9:LMT31.

Article CAS PubMed PubMed Central Google Scholar
Nishioka N, Naito T, Miyawaki T, Yabe M, Doshita K, Kodama H, et al. Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer. Thorac Cancer. 2022;13:1496–504.

Article CAS PubMed PubMed Central Google Scholar
Guller M, Herberg M, Amin N, Alkhatib H, Maroun C, Wu E, et al. Nutritional status as a predictive biomarker for immunotherapy outcomes in advanced head and neck cancer. Cancers. 2021;13:5772.

Article CAS PubMed PubMed Central Google Scholar
Johannet P, Sawyers A, Qian Y, Kozloff S, Gulati N, Donnelly D, et al. Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J Immunother Cancer. 2020;8:e001674.

Article PubMed PubMed Central Google Scholar
Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol. 2020;6:512–8.

Article PubMed Google Scholar
Antoun S, Lanoy E, Ammari S, Farhane S, Martin L, Robert C, et al. Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. Eur J Cancer. 2023;178:49–59.

Article PubMed Google Scholar
McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19:310–22.

Article PubMed PubMed Central Google Scholar
Richtig G, Hoeller C, Wolf M, Wolf I, Rainer BM, Schulter G, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study. PLoS ONE. 2018;13:e0204729.

Article PubMed PubMed Central Google Scholar
Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019;7:57.

Article PubMed PubMed Central Google Scholar
Jain A, Zhang S, Shanley RM, Fujioka N, Kratzke RA, Patel MR, et al. Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade. Cancer Immunol Immunother. 2022;72:1225–32.
Esposito A, Marra A, Bagnardi V, Frassoni S, Morganti S, Viale G, et al. Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: a multi-parametric analysis. Eur J Cancer. 2021;145:197–209.

Article CAS PubMed Google Scholar
Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–47.

Article PubMed Google Scholar
Pozzuto L, Silveira MN, Mendes MCS, Macedo LT, Costa FO, Martinez CAR, et al. Myosteatosis differentially affects the prognosis of non-metastatic colon and rectal cancer patients: an exploratory study. Front Oncol. 2021;11:762444.

Article CAS PubMed PubMed Central Google Scholar
Wang Y, Chen P, Huang J, Liu M, Peng D, Li Z, et al. Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy. Ann Transl Med. 2021;9:1801.

Article CAS PubMed PubMed Central Google Scholar
Tenuta M, Gelibter A, Pandozzi C, Sirgiovanni G, Campolo F, Venneri MA, et al. Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (NCSCL) treated with immune checkpoint inhibitors (ICIs): a prospective study. Cancers. 2021;13:6355.

Article CAS PubMed PubMed Central Google Scholar
Takenaka Y, Takemoto N, Otsuka T, Nishio M, Tanida M, Fujii T, et al. Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: a multicenter retrospective study. Oral Oncol. 2022;132:106018.

Article CAS PubMed Google Scholar
Deng HY, Chen ZJ, Qiu XM, Zhu DX, Tang XJ, Zhou Q. Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis. Nutrition. 2021;90:111345.

Article CAS PubMed Google Scholar
Lee D, Kim NW, Kim JY, Lee JH, Noh JH, Lee H, et al. Sarcopenia’s prognostic impact on patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Clin Med. 2021;10:5329.

Article CAS PubMed PubMed Central Google Scholar
Li S, Wang T, Tong G, Li X, You D, Cong M. Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2021;11:726257.

Article CAS PubMed PubMed Central Google Scholar
Takenaka Y, Oya R, Takemoto N, Inohara H. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. J Cachexia Sarcopenia Muscle. 2021;12:1122–35.

Article PubMed PubMed Central Google Scholar
Martini DJ, Kline MR, Liu Y, Shabto JM, Williams MA, Khan AI, et al. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer. 2020;126:575–82.

Article CAS PubMed Google Scholar
Wang J, Dong P, Qu Y, Xu W, Zhou Z, Ning K, et al. Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study. Eur Radiol. 2022;33:3232–42.
Minami S, Ihara S, Tanaka T, Komuta K. Sarcopenia and visceral adiposity did not affect efficacy of immune-checkpoint inhibitor monotherapy for pretreated patients with advanced non-small cell lung cancer. World J Oncol. 2020;11:9–22.

Article CAS PubMed PubMed Central Google Scholar
Martini DJ, Olsen TA, Goyal S, Liu Y, Evans ST, Magod B, et al. Body composition variables as radiographic biomarkers of clinical outcomes in metastatic renal cell carcinoma patients receiving immune checkpoint inhibitors. Front Oncol. 2021;11:707050.

Article CAS PubMed PubMed Central Google Scholar
Martini DJ, Shabto JM, Goyal S, Liu Y, Olsen TA, Evans ST, et al. Body composition as an independent predictive and prognostic biomarker in advanced urothelial carcinoma patients treated with immune checkpoint inhibitors. Oncologist. 2021;26:1017–25.

Article CAS PubMed PubMed Central Google Scholar
Andoh A, Nishida A, Takahashi K, Inatomi O, Imaeda H, Bamba S, et al. Comparison of the gut microbial community between obese and lean peoples using 16S gene sequencing in a Japanese population. J Clin Biochem Nutr. 2016;59:65–70.

Article CAS PubMed PubMed Central Google Scholar
Companys J, Gosalbes MJ, Pla-Paga L, Calderon-Perez L, Llaurado E, Pedret A, et al. Gut microbiota profile and its association with clinical variables and dietary intake in overweight/obese and lean subjects: a cross-sectional study. Nutrients. 2021;13:2032.

Article CAS PubMed PubMed Central Google Scholar
Allen JM, Mailing LJ, Niemiro GM, Moore R, Cook MD, White BA, et al. Exercise alters gut microbiota composition and function in lean and obese humans. Med Sci Sports Exerc. 2018;50:747–57.

Article PubMed Google Scholar
Gruneck L, Kullawong N, Kespechara K, Popluechai S. Gut microbiota of obese and diabetic Thai subjects and interplay with dietary habits and blood profiles. PeerJ. 2020;8:e9622.

Article PubMed PubMed Central Google Scholar
Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, et al. Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC Gastroenterol. 2015;15:100.

Article PubMed PubMed Central Google Scholar
Beaumont M, Goodrich JK, Jackson MA, Yet I, Davenport ER, Vieira-Silva S, et al. Heritable components of the human fecal microbiome are associated with visceral fat. Genome Biol. 2016;17:189.

Article PubMed PubMed Central Google Scholar
Maldonado-Contreras A, Noel SE, Ward DV, Velez M, Mangano KM. Associations between diet, the gut microbiome, and short-chain fatty acid production among older Caribbean latino adults. J Acad Nutr Diet. 2020;120:2047–60.e6.

Article PubMed Google Scholar
Nie X, Chen J, Ma X, Ni Y, Shen Y, Yu H, et al. A metagenome-wide association study of gut microbiome and visceral fat accumulation. Comput Struct Biotechnol J. 2020;18:2596–609.

Article CAS PubMed PubMed Central Google Scholar
Lahiri S, Kim H, Garcia-Perez I, Reza MA, Martin A, Cox KM, et al. The gut microbiota influences skeletal muscle mass and function in mice. Sci Transl Med. 2019;11:eaan5662.

Article PubMed PubMed Central Google Scholar
Clarke SF, Murphy EF, O’Sullivan O, Lucey AJ, Humphreys M, Hogan A, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014;63:1913–20.

Article CAS PubMed Google Scholar
Lv WQ, Lin X, Shen H, Liu HM, Qiu X, Li BY, et al. Human gut microbiome impacts skeletal muscle mass via gut microbial synthesis of the short-chain fatty acid butyrate among healthy menopausal women. J Cachexia Sarcopenia Muscle. 2021;12:1860–70.

Article PubMed PubMed Central Google Scholar
Fruge AD, Van der Pol W, Rogers LQ, Morrow CD, Tsuruta Y, Demark-Wahnefried W. Fecal Akkermansia muciniphila is associated with body composition and microbiota diversity in overweight and obese women with breast cancer participating in a presurgical weight loss trial. J Acad Nutr Diet. 2020;120:650–9.

Article PubMed Google Scholar
Bressa C, Bailen-Andrino M, Perez-Santiago J, Gonzalez-Soltero R, Perez M, Montalvo-Lominchar MG, et al. Differences in gut microbiota profile between women with active lifestyle and sedentary women. PLoS ONE. 2017;12:e0171352.

Article PubMed PubMed Central Google Scholar
Picca A, Ponziani FR, Calvani R, Marini F, Biancolillo A, Coelho-Junior HJ, et al. Gut microbial, inflammatory and metabolic signatures in older people with physical frailty and sarcopenia: results from the BIOSPHERE study. Nutrients. 2019;12:65.

Article PubMed PubMed Central Google Scholar
Ticinesi A, Mancabelli L, Tagliaferri S, Nouvenne A, Milani C, Del Rio D, et al. The gut-muscle axis in older subjects with low muscle mass and performance: a proof of concept study exploring fecal microbiota composition and function with shotgun metagenomics sequencing. Int J Mol Sci. 2020;21:8946.

Article CAS PubMed PubMed Central Google Scholar
Kang L, Li P, Wang D, Wang T, Hao D, Qu X. Alterations in intestinal microbiota diversity, composition, and function in patients with sarcopenia. Sci Rep. 2021;11:4628.

Article CAS PubMed PubMed Central Google Scholar
Schneeberger M, Everard A, Gomez-Valades AG, Matamoros S, Ramirez S, Delzenne NM, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep. 2015;5:16643.

Article CAS PubMed PubMed Central Google Scholar
Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65:426–36.

Article CAS PubMed Google Scholar
Ozato N, Saito S, Yamaguchi T, Katashima M, Tokuda I, Sawada K, et al. Blautia genus associated with visceral fat accumulation in adults 20–76 years of age. NPJ Biofilms Microbiomes. 2019;5:28.

Article PubMed PubMed Central Google Scholar
Chen YR, Zheng HM, Zhang GX, Chen FL, Chen LD, Yang ZC. High oscillospira abundance indicates constipation and low BMI in the Guangdong Gut Microbiome Project. Sci Rep. 2020;10:9364.

Article CAS PubMed PubMed Central Google Scholar
Osborne G, Wu F, Yang L, Kelly D, Hu J, Li H, et al. The association between gut microbiome and anthropometric measurements in Bangladesh. Gut Microbes. 2020;11:63–76.

Article CAS PubMed Google Scholar
Chandra RK, Baker M, Kumar V. Body composition, albumin levels, and delayed cutaneous cell-mediated immunity. Nutr Res. 1985;5:679–84.

Article Google Scholar
Wing EJ, Magee DM, Barczynski LK. Acute starvation in mice reduces the number of T cells and suppresses the development of T-cell-mediated immunity. Immunology. 1988;63:677–82.

CAS PubMed PubMed Central Google Scholar
Shimizu T, Miyake M, Hori S, Ichikawa K, Omori C, Iemura Y, et al. Clinical impact of sarcopenia and inflammatory/nutritional markers in patients with unresectable metastatic urothelial carcinoma treated with pembrolizumab. Diagnostics. 2020;10:310.

Article CAS PubMed PubMed Central Google Scholar
Cain EH, Saha A, Harowicz MR, Marks JR, Marcom PK, Mazurowski MA. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. Breast Cancer Res Treat. 2019;173:455–63.

Article CAS PubMed Google Scholar
Zhang Z, He T, Huang L, Ouyang Y, Li J, Huang Y, et al. Two precision medicine predictive tools for six malignant solid tumors: from gene-based research to clinical application. J Transl Med. 2019;17:405.

Article CAS PubMed PubMed Central Google Scholar
Zhang Z, Huang L, Li J, Wang P. Bioinformatics analysis reveals immune prognostic markers for overall survival of colorectal cancer patients: a novel machine learning survival predictive system. BMC Bioinforma. 2022;23:124.

Article CAS Google Scholar
Cheng T, Zhan X. Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J. 2017;8:51–60.

Article CAS PubMed PubMed Central Google Scholar
Cutler A, Breiman L. Archetypal analysis. Technometrics. 1994;36:338–47.

Article Google Scholar
Mørup M, Hansen LK. Archetypal analysis for machine learning and data mining. Neurocomputing. 2012;80:54–63.

Article Google Scholar
Dong M, Li L, Chen M, Kusalik A, Xu W. Predictive analysis methods for human microbiome data with application to Parkinson’s disease. PLoS ONE. 2020;15:e0237779.

Article CAS PubMed PubMed Central Google Scholar
Bartell JA, Sommer LM, Haagensen JAJ, Loch A, Espinosa R, Molin S, et al. Evolutionary highways to persistent bacterial infection. Nat Commun. 2019;10:629.

Article CAS PubMed PubMed Central Google Scholar
Aubert O, Higgins S, Bouatou Y, Yoo D, Raynaud M, Viglietti D, et al. Archetype analysis identifies distinct profiles in renal transplant recipients with transplant glomerulopathy associated with allograft survival. J Am Soc Nephrol. 2019;30:625–39.

Article CAS PubMed PubMed Central Google Scholar

Download references

Funding

This work was supported by funding from the Peter Brojde Lung Cancer Centre, Montreal, CA.

Author information

Authors and Affiliations

Peter Brojde Lung Cancer Centre, Segal Cancer Center, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada

Cecilia Hes & R. Thomas Jagoe
Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, H4A 3J1, Canada

Cecilia Hes & R. Thomas Jagoe
Research Center of the Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, QC, H2X 0A9, Canada

Cecilia Hes

Contributions

CH and RTJ conceived and planned the review. CH drew the figures. Both authors contributed to writing the manuscript.

Corresponding author

Correspondence to R. Thomas Jagoe.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.